AZNAstrazeneca PLC

Quotes delayed by up to 15 minutes · informational, not investment advice

Escopo e origem dos dados

Ativo: AZN
Moeda das demonstrações: USD
Último período anual nesta tabela: 2025-12-31
Fonte das demonstrações: SEC EDGAR

Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.

Fontes e metodologia

About the company

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagris…

IndustryDrug Manufacturers - General

Official website →

Smart calendar

Organizing upcoming events...

Key metrics

What the market pays

P/E

Price divided by trailing 12-month earnings

24.94×

P/B

Price divided by book value

5.14×

EV/EBITDA

Enterprise value divided by operating cash generation

14.04×

EV/Revenue

Enterprise value divided by revenue

4.69×

What the company earns

ROE

Return on shareholders’ equity

21.7%

ROA

Return on all assets

Gross margin

What remains after product costs

79.3%

Operating margin

What remains after operating the business

22.7%

Net margin

How much of each revenue unit becomes profit

17%

What it owes

Debt / Equity

Debt for each unit of shareholders’ equity

0.64

Total debt

Sum of borrowings

$32.2B

Cash

Cash available to cover it

$4.89B

Current ratio

Short-term assets divided by short-term liabilities

0.89

Free cash flow

Cash left after investing

$2.13B

Risk and growth

Beta

Moves more (>1) or less (<1) than the market

0.21

Revenue growth

Compared with the same period a year earlier

6.4%

Earnings growth

Compared with the same period a year earlier

2.3%

Dividend yield

Trailing 12-month distributions divided by price

1.9%

Market data provider figures for the latest published period. Informational, not investment advice.

Financial statements(USD)

Income statement

	2022	2023	2024	2025
Receita	44.35B	45.81B	54.07B	58.74B
Custo dos produtos	-12.39B	-8.27B	-10.21B	-10.63B
Lucro bruto	31.96B	37.54B	43.87B	48.11B
Pesquisa e desenvolvimento	-9.76B

News about AZN

Yahoo Finance · 4 days ago

	2022	2023	2024	2025
Ativo total	96.48B	101.12B	104.04B	114.07B
Ativo circulante	22.59B	25.05B	25.83B	28.72B
Caixa e equivalentes	6.17B	5.84B	5.49B	5.71B
Contas a receber	10.52B	12.13B	12.97B	15.18B
Estoques	4.7B	5.42B	5.29B	6.56B
Imobilizado	8.51B	9.4B	10.25B	12.96B
Passivo total	59.43B	61.95B	63.16B	65.36B
Passivo circulante	26.29B	30.54B	27.87B	30.62B
Dívida de longo prazo	22.97B	22.37B	26.51B	24.72B
Patrimônio líquido	37.06B	39.17B	40.87B	48.72B

AZNAstrazeneca PLC

Escopo e origem dos dados

About the company

Smart calendar

Key metrics

What the market pays

What the company earns

What it owes

Risk and growth

Financial statements(USD)

Income statement

News about AZN

AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed

AstraZeneca Earnings & Forecasts - Benzinga

AstraZeneca’s pipeline: six 2027 readouts that could reshape the growth story

Deutsche Bank turns neutral on AstraZeneca after breast cancer trial setback

Deutsche Bank muda para neutro em AstraZeneca após revés em ensaio de câncer de mama

Balance sheet

Remédio da AstraZeneca para câncer de mama não atinge objetivo em estudo avançado